Identification of an adaptor protein that facilitates Nrf2-Keap1 complex formation and modulates antioxidant response

Free Radical Biology and Medicine

Volumn 97, Issue , 2016, Pages 38-49

  Zhang, Yuxue ^a   Hou, Yongfan ^a   Liu, Chunchun ^a   Li, Yinlong ^b   Guo, Weiwei ^a   Wu, Jiu Lin ^c   Xu, Daqian ^a   You, Xue ^a,d   Pan, Yi ^a   Chen, Yan ^a  

^a UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^b CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^c FUZHOU UNIVERSITY   (China)

^d SHANGHAITECH UNIVERSITY   (China)

Author keywords

Antioxidant; Golgi apparatus; Keap1; Nrf2; PAQR3; Ubiquitination

Indexed keywords

GLUTAMATE CYSTEINE LIGASE; GLUTATHIONE TRANSFERASE A1; GLUTATHIONE TRANSFERASE A3; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE M3; HEME OXYGENASE 1; HYDROGEN PEROXIDE; KELCH LIKE ECH ASSOCIATED PROTEIN 1; MEMBRANE PROTEIN; PAQR3 PROTEIN; REACTIVE OXYGEN METABOLITE; TERT BUTYLHYDROQUINONE; TRANSCRIPTION FACTOR MAF; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; ANTIOXIDANT; KEAP1 PROTEIN, HUMAN; NFE2L2 PROTEIN, HUMAN; RKTG PROTEIN, HUMAN; SIGNAL PEPTIDE;

ANTIOXIDANT RESPONSIVE ELEMENT; ARTICLE; CELLULAR DISTRIBUTION; COMPLEX FORMATION; CONTROLLED STUDY; DOWN REGULATION; ECTOPIC EXPRESSION; FEMALE; GENE EXPRESSION; GENE SILENCING; GOLGI COMPLEX; HEPG2 CELL LINE; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UBIQUITINATION; UPREGULATION; GENETICS; HEP-G2 CELL LINE; METABOLISM; OXIDATIVE STRESS;

ANTIOXIDANTS; GOLGI APPARATUS; HEP G2 CELLS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KELCH-LIKE ECH-ASSOCIATED PROTEIN 1; MEMBRANE PROTEINS; NF-E2-RELATED FACTOR 2; OXIDATIVE STRESS; PROTEOLYSIS; REACTIVE OXYGEN SPECIES; UBIQUITINATION;

EID: 84971672039     PISSN: 08915849     EISSN: 18734596     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2016.05.017     Document Type: Article

References (41)

1. T. Suzuki, and M. Yamamoto Molecular basis of the Keap1-Nrf2 system Free Radic. Biol. Med. 88 2015 93 100
2. P. Moi, K. Chan, I. Asunis, A. Cao, and Y.W. Kan Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region Proc. Natl. Acad. Sci. USA 91 1994 9926 9930
3. R. Venugopal, and A.K. Jaiswal Nrf1 and Nrf2 positively and c-Fos and Fra1 negatively regulate the human antioxidant response element-mediated expression of NAD(P)H:quinone oxidoreductase1 gene Proc. Natl. Acad. Sci. USA 93 1996 14960 14965
4. J. Alam, D. Stewart, C. Touchard, S. Boinapally, A.M. Choi, and J.L. Cook Nrf2, a Cap'n'Collar transcription factor, regulates induction of the heme oxygenase-1 gene J. Biol. Chem. 274 1999 26071 26078
5. W.A. Solis, T.P. Dalton, M.Z. Dieter, S. Freshwater, J.M. Harrer, L. He, H.G. Shertzer, and D.W. Nebert Glutamate-cysteine ligase modifier subunit: mouse Gclm gene structure and regulation by agents that cause oxidative stress Biochem. Pharmacol. 63 2002 1739 1754
6. J.D. Hayes, S.A. Chanas, C.J. Henderson, M. McMahon, C. Sun, G.J. Moffat, C.R. Wolf, and M. Yamamoto The Nrf2 transcription factor contributes both to the basal expression of glutathione S-transferases in mouse liver and to their induction by the chemopreventive synthetic antioxidants, butylated hydroxyanisole and ethoxyquin Biochem. Soc. Trans. 28 2000 33 41
7. K. Itoh, T. Chiba, S. Takahashi, T. Ishii, K. Igarashi, Y. Katoh, T. Oyake, N. Hayashi, K. Satoh, I. Hatayama, M. Yamamoto, and Y. Nabeshima An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements Biochem. Biophys. Res. Commun. 236 1997 313 322
8. K. Itoh, J. Mimura, and M. Yamamoto Discovery of the negative regulator of Nrf2, Keap1: a historical overview Antioxid. Redox Signal. 13 2010 1665 1678
9. K. Itoh, N. Wakabayashi, Y. Katoh, T. Ishii, K. Igarashi, J.D. Engel, and M. Yamamoto Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain Genes Dev. 13 1999 76 86
10. A. Kobayashi, M.I. Kang, H. Okawa, M. Ohtsuji, Y. Zenke, T. Chiba, K. Igarashi, and M. Yamamoto Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2 Mol. Cell. Biol. 24 2004 7130 7139
11. T. Suzuki, H. Motohashi, and M. Yamamoto Toward clinical application of the Keap1-Nrf2 pathway Trends Pharmacol. Sci. 34 2013 340 346
12. R. Gold, L. Kappos, D.L. Arnold, A. Bar-Or, G. Giovannoni, K. Selmaj, C. Tornatore, M.T. Sweetser, M. Yang, S.I. Sheikh, K.T. Dawson, and D.S. Investigators Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis N. Engl. J. Med. 367 2012 1098 1107
13. R.J. Fox, D.H. Miller, J.T. Phillips, M. Hutchinson, E. Havrdova, M. Kita, M. Yang, K. Raghupathi, M. Novas, M.T. Sweetser, V. Viglietta, K.T. Dawson, and C.S. Investigators, Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis N. Engl. J. Med. 367 2012 1087 1097
14. Y.T. Tang, T. Hu, M. Arterburn, B. Boyle, J.M. Bright, P.C. Emtage, and W.D. Funk PAQR proteins: a novel membrane receptor family defined by an ancient 7-transmembrane pass motif J. Mol. Evol. 61 2005 372 380
15. T. Yamauchi, J. Kamon, Y. Ito, A. Tsuchida, T. Yokomizo, S. Kita, T. Sugiyama, M. Miyagishi, K. Hara, M. Tsunoda, K. Murakami, T. Ohteki, S. Uchida, S. Takekawa, H. Waki, N.H. Tsuno, Y. Shibata, Y. Terauchi, P. Froguel, K. Tobe, S. Koyasu, K. Taira, T. Kitamura, T. Shimizu, R. Nagai, and T. Kadowaki Cloning of adiponectin receptors that mediate antidiabetic metabolic effects Nature 423 2003 762 769
16. Y. Zhu, J. Bond, and P. Thomas Identification, classification, and partial characterization of genes in humans and other vertebrates homologous to a fish membrane progestin receptor Proc. Natl. Acad. Sci. USA 100 2003 2237 2242
17. L. Feng, X. Xie, Q. Ding, X. Luo, J. He, F. Fan, W. Liu, Z. Wang, and Y. Chen Spatial regulation of Raf kinase signaling by RKTG Proc. Natl. Acad. Sci. USA 104 2007 14348 14353
18. X. Luo, L. Feng, X. Jiang, F. Xiao, Z. Wang, G.S. Feng, and Y. Chen Characterization of the topology and functional domains of RKTG Biochem. J. 414 2008 399 406
19. F. Fan, L. Feng, J. He, X. Wang, X. Jiang, Y. Zhang, Z. Wang, and Y. Chen RKTG sequesters B-Raf to the Golgi apparatus and inhibits the proliferation and tumorigenicity of human malignant melanoma cells Carcinogenesis 29 2008 1157 1163
20. Y. Jiang, X. Xie, Y. Zhang, X. Luo, X. Wang, F. Fan, D. Zheng, Z. Wang, and Y. Chen Regulation of G-protein signaling by RKTG via sequestration of the G betagamma subunit to the Golgi apparatus Mol. Cell. Biol. 30 2010 78 90
21. X. Wang, L. Wang, L. Zhu, Y. Pan, F. Xiao, W. Liu, Z. Wang, F. Guo, Y. Liu, W.G. Thomas, and Y. Chen PAQR3 modulates insulin signaling by shunting phosphoinositide 3-kinase p110alpha to the Golgi apparatus Diabetes 62 2013 444 456
22. X. Xie, Y. Zhang, Y. Jiang, W. Liu, H. Ma, Z. Wang, and Y. Chen Suppressive function of RKTG on chemical carcinogen-induced skin carcinogenesis in mouse Carcinogenesis 29 2008 1632 1638
23. Y. Jiang, X. Xie, Z. Li, Z. Wang, Y. Zhang, Z.Q. Ling, Y. Pan, Z. Wang, and Y. Chen Functional cooperation of RKTG with p53 in tumorigenesis and epithelial-mesenchymal transition Cancer Res. 71 2011 2959 2968
24. X. Wang, X. Li, F. Fan, S. Jiao, L. Wang, L. Zhu, Y. Pan, G. Wu, Z.Q. Ling, J. Fang, and Y. Chen PAQR3 plays a suppressive role in the tumorigenesis of colorectal cancers Carcinogenesis 33 2012 2228 2235
25. Z.Q. Ling, W. Guo, X.X. Lu, X. Zhu, L.L. Hong, Z. Wang, Z. Wang, and Y. Chen A Golgi-specific protein PAQR3 is closely associated with the progression, metastasis and prognosis of human gastric cancers Ann. Oncol. 25 2014 1363 1372
26. H.G. Wu, W.J. Zhang, Q. Ding, G. Peng, Z.W. Zou, T. Liu, R.B. Cao, S.J. Fei, P.C. Li, K.Y. Yang, J.L. Hu, X.F. Dai, G. Wu, and P.D. Li Identification of PAQR3 as a new candidate tumor suppressor in hepatocellular carcinoma Oncol. Rep. 32 2014 2687 2695
27. L. Yu, L. Zhou, Y. Cheng, L. Sun, J. Fan, J. Liang, M. Guo, N. Liu, and L. Zhu MicroRNA-543 acts as an oncogene by targeting PAQR3 in hepatocellular carcinoma Am. J. Cancer Res. 4 2014 897 906
28. Y. Xiu, Z. Liu, S. Xia, C. Jin, H. Yin, W. Zhao, and Q. Wu MicroRNA-137 upregulation increases bladder cancer cell proliferation and invasion by targeting PAQR3 PLoS One 9 2014 e109734
29. Z. Ma, Y. Wang, T. Piao, Z. Li, H. Zhang, Z. Liu, and J. Liu The tumor suppressor role of PAQR3 in osteosarcoma Tumour Biol. 36 2015 3319 3324
30. Z. Li, Z.Q. Ling, W. Guo, X.X. Lu, Y. Pan, Z. Wang, and Y. Chen PAQR3 expression is downregulated in human breast cancers and correlated with HER2 expression Oncotarget 6 2015 12357 12368
31. X.J. Wang, J.D. Hayes, and C.R. Wolf Generation of a stable antioxidant response element-driven reporter gene cell line and its use to show redox-dependent activation of nrf2 by cancer chemotherapeutic agents Cancer Res. 66 2006 10983 10994
32. J.M. Lee, J.D. Moehlenkamp, J.M. Hanson, and J.A. Johnson Nrf2-dependent activation of the antioxidant responsive element by tert-butylhydroquinone is independent of oxidative stress in IMR-32 human neuroblastoma cells Biochem. Biophys. Res. Commun. 280 2001 286 292
33. Y. Zhang, X. Jiang, X. Qin, D. Ye, Z. Yi, M. Liu, O. Bai, W. Liu, X. Xie, Z. Wang, J. Fang, and Y. Chen RKTG inhibits angiogenesis by suppressing MAPK-mediated autocrine VEGF signaling and is downregulated in clear-cell renal cell carcinoma Oncogene 29 2010 5404 5415
34. P.A. Wender, D.J. Mitchell, K. Pattabiraman, E.T. Pelkey, L. Steinman, and J.B. Rothbard The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters Proc. Natl. Acad. Sci. USA 97 2000 13003 13008
35. M. Kobayashi, L. Li, N. Iwamoto, Y. Nakajima-Takagi, H. Kaneko, Y. Nakayama, M. Eguchi, Y. Wada, Y. Kumagai, and M. Yamamoto The antioxidant defense system Keap1-Nrf2 comprises a multiple sensing mechanism for responding to a wide range of chemical compounds Mol. Cell. Biol. 29 2009 493 502
36. I.M. Copple The Keap1-Nrf2 cell defense pathway - a promising therapeutic target? Adv. Pharmacol. 63 2012 43 79
37. Y.Y. Wang, Y.X. Yang, H. Zhe, Z.X. He, and S.F. Zhou Bardoxolone methyl (CDDO-Me) as a therapeutic agent: an update on its pharmacokinetic and pharmacodynamic properties Drug Des. Dev. Ther. 8 2014 2075 2088
38. K.T. Liby, and M.B. Sporn Synthetic oleanane triterpenoids: multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease Pharmacol. Rev. 64 4 2012 972 1003
39. D. de Zeeuw, T. Akizawa, P. Audhya, G.L. Bakris, M. Chin, H. Christ-Schmidt, A. Goldsberry, M. Houser, M. Krauth, H.J. Lambers Heerspink, J.J. McMurray, C.J. Meyer, H.H. Parving, G. Remuzzi, R.D. Toto, N.D. Vaziri, C. Wanner, J. Wittes, D. Wrolstad, G.M. Chertow, and B.T. Investigators Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease N. Engl. J. Med. 369 2013 2492 2503
40. S.L. Slocum, and T.W. Kensler Nrf2: control of sensitivity to carcinogens Arch. Toxicol. 85 2011 273 284
41. X.J. Wang, Z. Sun, N.F. Villeneuve, S. Zhang, F. Zhao, Y. Li, W. Chen, X. Yi, W. Zheng, G.T. Wondrak, P.K. Wong, and D.D. Zhang Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2 Carcinogenesis 29 2008 1235 1243